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Introduction
  Articular hyaline cartilage has poor regenerative capacity, 
and the loss of its function is, in the long term, often 
painful and debilitating. Th  erefore, attempts have been 
made to intervene in cartilage defects with the objective 
of supporting biological repair of tissue. Alongside cell-
based strategies for in situ regeneration [1], autologous 
chondrocyte transplantation was initiated as the ﬁ  rst cell 
therapy for cartilage [2]. Th  e requirement for biopsies 
from a healthy area of the cartilage cap and the necessity 
of surgical intervention prior to transplantation are 
evident disadvantages of this therapy, and multipotent 
mesenchymal stromal cells (MSCs) represent an appeal-
ing alternative cell source for cartilage repair.
Th   e therapeutic potential of MSCs for cartilage repair 
is clear; however, the requirements and conditions for 
eﬀ  ective induction of chondrogenesis in MSCs and for 
the production of a stable cartilaginous tissue by these 
cells are far from being understood. Diﬀ  erent sources of 
MSCs have been considered for cartilage tissue engineer-
ing, mainly based on criteria of availability, as for adipose 
tissue (AT), or of proximity to cartilage and the joint 
environment  in vivo, as for bone marrow (BM) and 
synovial tissues. Focussing on human MSCs, this review 
will provide an overview of studies featuring comparative 
analysis of the chondrogenic diﬀ   erentiation of MSCs 
from diﬀ  erent sources.
Defi  nition of multipotent mesenchymal stromal 
cells
Th  e presence of cells with osteochondral diﬀ  erentiation 
potential in BM was shown in the late 1960s [3]. Th  eir 
isolation as the adherent mononuclear cell fraction of 
BM and ex vivo cultivation allowed their further charac-
terization as colony-forming unit ﬁ  broblasts  (CFU-Fs) 
[4]. Th   is pioneering work in guinea-pig was followed by 
the identiﬁ   cation of human BM CFU-Fs [5] and the 
demonstration of their osteogenic potential in diﬀ  usion 
chambers [6]. Th  e  in vitro diﬀ  erentiation of cloned MSC 
populations along the osteogenic, chondrogenic and 
adipogenic lineages demonstrated the multilineage 
potential of these cells [7].
Th  e diﬀ  erentiation potential of MSCs was the feature 
that fostered their discovery and characterization. In 
vivo, MSCs function to support the homeostasis of 
mesenchymal tissues, and this mesengenic activity bears 
high therapeutic potential. However, it has been recog-
nized in recent years that the potential therapeutic 
beneﬁ  ts of MSCs do not reside solely in their ability to 
diﬀ   erentiate towards multiple lineages but also in 
paracrine mechanisms [8]. In particular, the cardio-
vascular reparative eﬀ  ects attributed to MSCs appear to 
be mediated predominantly through the secretion of 
factors targeting cells at the site of repair [9]. Indeed, 
MSCs secrete a variety of bioactive molecules with 
trophic, immunomodulatory, anti-scarring and chemo-
attractant activities [10]. New therapeutic strategies thus 
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haematopoietic engraftment or for immunosuppression 
in graft-versus-host disease [11]. Whether beneﬁ  cial 
eﬀ   ects can be expected from the immunomodulatory 
activities of MSCs for the treatment of rheumatic 
arthritis is still under debate [12].
Th  e term ‘mesenchymal stem cells’ was proposed by 
Caplan [13] on the basis of the ability of these cell 
populations to diﬀ   erentiate towards tissues of mesen-
chymal origin. Based on diﬀ  erent isolation methods to 
obtain MSCs or subpopulations of MSCs, investigators 
have given diﬀ  erent names, such as bone marrow stromal 
cells (BMSCs) [14], marrow-isolated adult multipotent 
inducible (MIAMIs) cells [15] or multipotent adult 
progenitor cells (MAPCs) [16] to these cell populations. 
Th   e International Society for Cellular Th  erapy  proposed 
the term ‘multipotent mesenchymal stromal cell’ for the 
plastic-adherent cell population isolated from BM or 
other tissues, thus avoiding use of the term ‘stem cells’ to 
designate a population that does not consist entirely of 
such cells [17].
Indeed, early evidence for heterogeneity of MSC popu-
lations in terms of morphology, growth characteristics 
and diﬀ  erentiation potential has been reported [18]. MSC 
populations are heterogeneous cell populations whose 
composition depends on isolation methods and 
expansion conditions that diﬀ  er largely among investi-
gators. A recent publication on cloned populations of 
MSCs showed that nearly 50% of CFU-Fs from BM were 
tripotent MSCs while the remaining population of cells 
showed varied phenotypes [19].
So far, no clear marker for MSCs has been identiﬁ  ed. 
Th  e criteria for the deﬁ  nition of MSCs, as set by the 
International Society for Cellular Th   erapy, are the ability 
of MSCs to adhere to plastic in standard culture 
conditions, their phenotypical characterization based on 
the expression of a set of surface antigens and their in 
vitro diﬀ  erentiation along the osteogenic, the adipogenic 
and the chondrogenic lineages [20]. Th  e ability to form 
CFU-Fs is another commonly accepted criterion. How-
ever, none of these criteria is unequivocal and only their 
combination can be used to deﬁ  ne MSC populations.
Sources of MSCs in diff  erent organs
While it was the characterization of BM stromal cells that 
introduced the concept of MSCs, analysis of progenitor 
cell populations isolated from other tissues showed that 
they shared the properties ascribed to BM MSCs. Th  is 
was not restricted to mesodermal tissues, on which this 
review will focus, as MSCs have also been isolated from 
ectodermal tissues, such as skin or hair follicles, as well as 
from perinatal tissue and umbilical cord blood [21].
Th  e multilineage diﬀ   erentiation potential of a cell 
population can be due to a mixture of diﬀ  erent 
committed progenitor cells. Th  erefore, to demonstrate 
the presence of multipotent cells in a cell population, it is 
essential to show the multilineage potential of cloned cell 
populations. A tissue other than BM whose osteogenic 
properties were described at an early stage was the 
periosteum [22], in which the presence of clonogenic 
multipotent cells has been demonstrated [23]. Th  e 
presence of MSCs was also demonstrated in stromal cells 
isolated from AT [24]. Th  e synovial membrane (SM) 
appeared a particularly interesting source of cells for 
cartilage tissue engineering owing to its proximity to 
articular cartilage. Th  e presence of MSCs with multi-
lineage potential was shown in the SM of healthy and 
osteoarthritic patients [25]. A more extended analysis of 
clonal populations of SM MSCs distinguished two popu-
lations: 30% of cells were tripotent while the remainder 
displayed only osteo-chondral diﬀ  erentiation  potential 
[26]. Th   is heterogeneity could be linked to the presence 
of synovial ﬁ  broblasts among SM MSC populations. Th  e 
presence of MSCs has also been demonstrated in the 
synovial ﬂ   uid of healthy and arthritic patients [27]. 
Dediﬀ  erentiated chondrocytes from articular cartilage of 
healthy and osteoarthritic donors have been shown to 
exhibit MSC characteristics. Th  e reported rates of 
tripotent cloned cell populations arising from them 
varies from 10% to 30% [28,29]. In trabecular bone, cell 
populations with chondrogenic, osteogenic and adipo-
genic diﬀ  erentiation potential have been isolated [30], 
but the multidiﬀ  erentiation potential of cloned popula-
tions has been shown only along the adipogenic and 
osteogenic lineages [31].
Putative MSC populations have also been isolated from 
other tissues, for which, to our knowledge, the 
demonstration of clonal multilineage potential has not 
been provided. Th   ese tissues include muscle [32] as well 
as joint-related tissues such as meniscus, intra-articular 
ligament [33] and infrapatellar fat pad [34].
Origin of MSCs in vivo
MSCs are deﬁ   ned and characterized as cultured cell 
populations. Th   e low numbers of initial cells isolated from 
tissue and the lack of unequivocal markers hampered the 
investigation of their physiological location and function 
in vivo. Pericytes, a cell type found in close proximity to 
endothelial cells in capillaries and micro  vessels, have been 
reported to possess stem cell proper  ties [35,36] and this 
gave rise to the hypothesis that MSCs and pericytes might 
represent one cell type. Markers for pericytes include the 
adhesion molecule CD146, whose expression in BM is 
restricted to adventitial reticular cells in the subendothelial 
layer of sinusoids [37]. A CD146-positive population of 
subendothelial cells from human BM stroma is the ﬁ  rst 
and so far only MSC entity for which true self-renewing 
capacity has been demonstrated [37].
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restricted to BM. Based on the expression of CD146 and 
other markers, pericytes have been identiﬁ  ed in multiple 
human organs, including skeletal muscle, pancreas, 
adipose tissue and placenta, and clonogenic populations 
from these cell populations have been found to display 
osteogenic, chondrogenic and adipogenic diﬀ  erentiation 
potential [38]. Possibly, MSCs derived from all vascu  lar-
ized tissues, such as BM, AT, trabecular bone, periosteum 
and SM, could share a common origin as perivascular 
cells. Evidence for this common origin of MSCs is so far 
based on similarities between MSCs and pericytes and 
on the shared expression of marker genes. Further 
investigations are needed to test this hypothesis.
However, cells with MSC characteristics have also been 
isolated from articular cartilage, which is an avascular 
tissue [28,29]. Provided the tissue of origin was not 
contaminated, a perivascular origin of these cells can be 
excluded. It is likely, therefore, that cells other than 
perivascular cells can contribute to multipotent MSC 
populations.
Numbers of MSCs in diff  erent tissues
In relation to tissue mass, yields of adherent stromal cells 
from BM and AT have been described as similar, with an 
average 2 × 105 cells per gram of tissue [39]. As AT MSCs 
are most frequently isolated from lipoaspirates, no 
correlation to initial tissue mass is possible. Th  e total 
number of nucleated cells is much higher in BM than in 
AT and, accordingly, investigators have reported higher 
amounts of CFU-Fs per total cell number in AT [33,40]. 
Identical yields of CFU-Fs per total cell number were 
shown from periosteum and from AT [41], while more 
CFU-Fs could be isolated from SM than from 
subcutaneous fat [41,42] or infrapatellar fat [43].
Th  e analysis of diﬀ  erences in the growth kinetics of 
MSCs from diﬀ   erent sources would require precise 
monitoring of initial cell numbers. It is not clear whether 
longer growth potential of AT MSCs than of BM MSCs 
before senescence, as suggested by some studies 
[40,44,45], can be convincingly demonstrated. Th  e  better 
growth characteristics sometimes reported for AT MSCs 
may, instead, be linked to higher initial cell numbers. In 
terms of accessibility and yield of adherent cells, AT 
indeed appears one of the most attractive sources of 
MSCs for therapeutic use.
Molecular characterization of MSCs
No speciﬁ   c marker combination for MSCs has been 
identiﬁ  ed so far. However, immunophenotypical proﬁ  les 
of expanded MSCs from diﬀ  erent sources have generally 
been found to be very similar. Th   e analysis of MSCs from 
BM, AT, SM and periosteum showed that these cells can 
be characterized by the absence of expression of surface 
markers for the haematopoietic lineage, such as the 
cluster of diﬀ  erentiation (CD) molecules CD14, CD31 or 
CD45, and by positivity for a panel of markers, including 
CD13, CD29, CD44, CD73, CD90, CD105, CD147 or 
CD166 [33,40,41,44,46-53]. Results from ﬂ  ow cytometric 
analysis of MSCs showing signiﬁ  cant diﬀ  erences between 
diﬀ  erent sources are summarized in Table 1.
While absence of CD34 is generally considered as a 
criterion for the deﬁ  nition of MSCs [20], some investi-
gators have reported low expression in AT MSCs 
[46,51,53] and one group described selected cell 
populations with multidiﬀ  erentiation potential from AT 
using CD34 [54]. Th  e presence of a pericytic CD34-
positive subpopulation in AT has been shown, but it has 
not yet been determined by cloning studies whether 
these cells indeed bear stem cell charac  teristics [55,56]. 
While the stem cell marker CD133 is not expressed in 
expanded MSC populations obtained by adhesion to 
plastic [40,47], the isolation of CD133-positive cell 
populations from blood and BM with high proliferation 
potential and multilineage potential, including 
mesodermal lineages, has been described [57,58]. CD271, 
a marker that is highly expressed in BM and AT MSCs 
and allows the isolation of MSC populations from 
primary tissues [54,59], has been reported not to be 
expressed in SM MSCs [26,60]. However, to our 
knowledge, no direct comparison of stem cell populations 
from diﬀ   erent sources has been performed for this 
marker. Several studies have pointed to higher expression 
of CD106 in BM than in AT [40,46,53,61]. Th  e  vascular 
cell adhesion molecule CD106/VCAM1 has been shown 
to be involved in homing of haematopoietic stem cells 
(HSCs) [62]. Th  is  diﬀ  erence may, therefore, be related to 
the speciﬁ   c micro  environment in BM and has indeed 
been correlated with a functional diﬀ  erence between AT 
and BM MSCs, the latter showing a higher capacity to 
maintain long-term cultures of primary HSCs [63]. 
Another marker with potential functional relevance is 
the platelet-derived growth factor receptor CD140a/
PDGFRα, which is involved in proliferation and 
migration of MSCs and osteoblasts and has been 
Table 1. Surface markers for which diff  erent expression 
profi  les in human MSCs from adipose tissue (AT), bone 
marrow (BM) and synovial membrane (SM) have been 
reported
AT > BMa  BM > AT  SM > BM  BM > SM
CD34 [51]  CD106 [40,61]  CD140a [64]  CD90 [48]
 CD146  [61]   
 HLA-ABC  [61]   
aHigher expression in multipotent mesenchymal stromal cells from adipose 
tissue than from bone marrow. AT, adipose tissue; BM, bone marrow; HLA, 
human leukocyte antigen; SM, synovial membrane.
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SM than in BM [64].
Comparative array analysis of expanded MSCs from 
diﬀ  erent sources was published by several groups and 
provided, overall, very similar expression proﬁ  les of MSC 
populations [44,47,48,65-67]. Interestingly, intra-articular 
MSCs from SM and MSC-like cells from anterior cruciate 
ligament and meniscus were found to cluster separately 
from AT, BM and muscle MSCs [33]. Similar results were 
found by two-dimensional gel electrophoresis analysis of 
the proteome of MSCs, where the expression proﬁ  les of 
AT and BM MSCs were closer to each other than either 
was to SM MSCs [53]. While the functional heterogeneity 
of SM MSCs has been characterized [26], it remains 
unknown for other intra-articular sources of cells. It is 
not clear, therefore, whether the separate clustering of 
SM MSCs is due to particular characteristics of MSCs 
from the joint environment or to a higher heterogeneity 
of these populations. Altogether, the comparative trans-
criptome analyses of MSCs from diﬀ  erent sources have 
revealed few diﬀ  erences, suggesting that these cell popu-
lations contain a common population of similar cells.
Epigenetic characterization of MSCs
Large-scale analysis of DNA methylation in embryonic 
and adult stem cells has shown that embryonic stem (ES) 
cells can clearly be discriminated from MSCs by speciﬁ  c 
hypermethylation of numerous genes. In contrast, the 
comparison of AT and BM MSCs revealed few diﬀ  erences 
[66]. A comparison of DNA methylation proﬁ  les in MSCs 
from AT, BM and muscle and in HSCs also revealed 
speciﬁ  c hypermethylation of numerous genes in HSCs 
while the methylation patterns of MSCs from diﬀ  erent 
sources were very similar. Most promoters specifying 
mesodermal, endodermal and ectodermal diﬀ  erentiation 
were hypomethylated in all MSC populations [68]. Th  is 
suggests that promoter hypomethylation is not predictive 
for the diﬀ   erentiation potential of cells, while hyper-
methy  lation sets restrictions that deﬁ   ne frames for 
diﬀ  erentiation potentials, distinguishing MSCs from ES 
cells or HSCs.
Accordingly, genes related to the adipogenic and 
myogenic lineage were found to be equally hypo-
methylated in MSCs from AT, BM or muscle [69], and in 
an analysis of the methylation patterns in the promoters 
of  COL2A1 (collagen type II gene) and COL10A1 
(collagen type X gene) in MSCs we found no diﬀ  erences 
between BM- and AT-derived MSCs [70]. However, two 
cytosines in the COL10A1 promoter were consistently 
hypomethylated in MSCs in comparison with articular 
chondrocytes, correlating to the inducibility of COL10A1 
expression and hypertrophy during in vitro chondro-
genesis of MSCs [70]. Diﬀ   erences between the DNA 
methylation patterns of diﬀ   erentiated cells originating 
from embryonic precursors and MSCs could thus be of 
functional relevance for tissue engineering.
Post-translational histone modiﬁ   cations have been 
mapped in ES cells and in MSCs and have been recog-
nized to play an important role in transcriptional 
regulation in stem cells [71]. To date, no comparative 
analysis of MSCs from diﬀ   erent sources has been 
published. Histone modiﬁ  cations and histone-modifying 
molecules are regulated, while MSCs enter senescence in 
vitro and could be involved in the ensuing loss of 
diﬀ   erentiation potential [72]. Th  ey are also actively 
involved in diﬀ  erentiation. Several studies have indicated 
that histone deacetylases, in particular HDAC4, may 
represent important regulators of chondrogenesis [73,74].
MicroRNAs represent a further epigenetic regulation 
mechanism relevant for stem cell biology [75]. Th  e 
comparison of the microRNA expression proﬁ  les  of 
MSCs from BM and AT revealed that only one 
microRNA was diﬀ  erentially expressed while the diﬀ  er-
ences with ES cells were high [66]. Studies have shown 
regulation of the expression of microRNAs in MSC 
senescence [76] and chondrogenic diﬀ  erentiation  [77], 
but the functional mechanisms are unknown. Th  e 
epigenetic characterization of MSCs is a relatively new 
ﬁ  eld of investigation that has so far revealed only minor 
diﬀ  erences between MSCs from diﬀ  erent sources at all 
levels. Reﬁ   nement of the analysis of proﬁ  les  may, 
however, lead to an epigenetic deﬁ  nition of MSCs, which 
could have the advantage of correlating with the 
functional potential of the cells.
Induction of chondrogenic diff  erentiation of MSCs 
in vitro
During embryogenesis the development of cartilage is 
initiated by a phase of condensation of mesenchymal 
precursor cells, and the cell-cell contact arising from 
condensation appears to be crucial for the onset of 
chondrogenesis [78]. N-cadherin seems to be involved in 
cell-cell contact in pre-cartilage condensations, and 
functional N-cadherin was necessary for chondrogenesis 
of chick limb mesenchymal cells in vitro and in vivo [79]. 
In human MSCs, N-cadherin is strongly up-regulated 
during the condensation phase during the ﬁ  rst few days 
of chondrogenic induction in vitro [80]. When MSCs are 
submitted to chondrogenic conditions in monolayer 
culture, they begin to condensate in response to the 
stimulus and form high-density three-dimensional cell 
aggregates [65]. However, proper chondrogenic 
diﬀ  erentiation occurs also for MSCs embedded in gel-
like biomaterials that keep cells apart from each other 
and thus limit direct cell-cell contact [81]. Th  is  suggests 
that, although cell-cell contact facilitates chondrogenic 
induction of MSCs compared with monolayer culture, it 
does not represent an absolute requirement for in vitro 
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dimensional structure.
One of the most widely applied culture systems for 
chondrogenesis is pellet culture, alternatively termed 
aggregate or spheroid culture [82,83]. Pellets comprising 
between 200,000 and 500,000 cells, depending on the 
investigators, are submitted to chondrogenic induction 
with a basal medium containing, conventionally, 
dexamethasone, ascorbate, insulin, transferrin and 
selenous acid [82,83]. Th   e classic growth factor 
supplementation for this medium is 10 ng/ml of 
transforming growth factor (TGF)β. TGFβ1, 2 and 3 are 
the only well-established full inducers of chondrogenesis 
that lead to deposition of proteoglycan and collagen type 
II when added as single factors [83,84]. Although other 
inducers of chondrogenesis, such as the bone morpho-
genic proteins BMP2 for BM MSCs and BMP6 for AT 
MSCs, have been described [85,86], this has not been 
conﬁ   rmed by other investigators [65,87-90] and may 
apply only to MSCs from selected donors. Rather, BMP2 
[85], BMP4 [91], BMP6 [92] and the insulin-lik    e growth 
factor IGF1 [87] may be regarded as promoters of 
chondrogenesis in MSCs when used together with the 
inducer TGFβ. Table  2 gives an overview of studies 
characterizing growth factors as full inducers or 
promoters of chondrogenesis in MSCs. Besides soluble 
factors, environmental factors such as mechanical stimu-
lation [93] and hypoxia [94,95] have also been reported to 
modulate chondrogenesis of MSCs in vitro.
With some exceptions [40], most studies undertaking a 
direct comparison of BM and AT MSCs have described a 
lower chondrogenic diﬀ  erentiation potential of AT MSCs 
in pellet culture under induction with TGFβ1 or 3 alone 
[61,65,96] or with TGFβ2 and IGF1 [97], including 
studies using cells isolated from the same patients 
[98,99]. Cultures in alginate beads [50,100], hyaluronic 
acid scaﬀ  olds [101] and cartilage-derived matrix [100] 
also showed a lower response of AT MSCs to TGFβ-
driven chondrogenic induction.
Looking for factors that might explain the reduced 
inducibility of AT MSCs with TGFβ, we analysed the 
expression of relevant growth factors in expanded MSCs 
from BM and AT and found reduced expression of 
BMP2, 4, 6 and the TGFβ receptor 1 (TGFBR1) in AT 
MSCs [89] and enhanced levels of the integral membrane 
protein 2A (ITM2A) gene [102]. Th   e high expression of 
ITM2A during the early phase of the induction of 
chondro  genesis correlated to inhibition of chondro-
genesis, and forced overexpression of ITM2A was indeed 
able to inhibit chondrogenesis in a mouse cell line [102].
One strategy explored for the enhancement of 
chondro  genesis in AT MSCs was to increase concen-
trations of TGFβ. While we found that concen  trations up 
to 50 ng/ml did not enhance the chondrogenesis of AT 
MSCs [89], another group found that a combination of 
25  ng/ml TGFβ2 and 500  ng/ml IGF1 induced a 
chondrogenic phenotype in AT MSCs similar to that 
induced by 5 ng/ml TGFβ2 in BM MSCs [103]. A second 
strategy arising from the diﬀ  erences in the growth factor 
repertoire of AT and BM MSCs was to add BMPs for the 
induction of chondrogenesis. Th   e addition of BMPs at a 
concentration of 10 ng/ml indeed enhanced the chondro-
genic diﬀ  erentiation of AT MSCs. Among the BMPs the 
most potent inducer was BMP6, which eliminated the 
diﬀ  erences in diﬀ  erentiation potential between AT and 
BM MSCs [45,89,100].
Th   e third source of MSCs often considered for 
applications in cartilage tissue engineering is the SM. 
While the chondrogenic potential of SM MSCs was 
initially described with TGFβ1 as inducing factor 
[25,104], another laboratory found no induction of 
chondro  genesis in pellet cultures with TGFβ3 alone, but 
Table 2. Growth factors reported as full inducers (I) or promoters (P) of chondrogenic diff  erentiation of human MSCs in 
pellet culture in vitro
  BM MSC  AT MSC  SM MSC
Factor  I P    I P    I P
TGFβ1  [84,96,98]          
TGFβ2  [84]          
TGFβ3 [40,61,65,83,  89,90,99]      [40]       
BMP2 [85,109]  [85,90]    [110]  [89]      [41,105]
BMP4   [90,91]      [89]     
BMP6   [45,87,90,92]    [86]  [45,89]      [52]
BMP7    [90]          [111]
IGF1   [87,90,97]      [103]      [112]
I, factors inducing proteoglycan and collagen type II deposition in pellets according to histology when added as single factors to chondrogenic basal medium; 
P, factors promoting proteoglycan and collagen type II deposition in pellets when added in combination with TGFβ to chondrogenic basal medium. The list of 
publications is not exhaustive. AT, adipose tissue; BM, bone marrow; BMP, bone morphogenic protein; IGF, insulin-like growth factor; MSC, multipotent mesenchymal 
stromal cell; SM, synovial membrane; TGF, transforming growth factor.
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[105]. Under these conditions with TGFβ3 and high-dose 
BMP2, chondrogenic diﬀ  erentiation was higher in MSCs 
from BM, SM and periosteum than in those from muscle 
and subcutaneous AT [41,42]. We found the response of 
SM MSCs to chondrogenic induction with TGFβ3 alone 
to be higher than that of AT MSCs, but lower than that of 
BM MSCs. While TGFβ3 was able to induce chondro-
genesis in only 50% of SM MSC populations from distinct 
donors, 100% of SM MSCs responded when TGFβ3 was 
combined with 10 ng/ml BMP6 [52].
Th   e requirements for the induction of chondrogenesis 
in MSCs from diﬀ  erent sources thus appear to diﬀ  er in 
terms of growth factors. Th   e comparative analysis of AT 
and BM suggests these diﬀ  erent requirements may be 
related to diﬀ   erences in the growth factor repertoires 
expressed by the cells or to active pathways at the time 
point of the initiation of chondrogenesis, which may 
depend on their microenvironment in vivo.
Hypertrophic diff  erentiation of MSCs in vitro
Despite diﬀ   erences in the conditions necessary for 
eﬀ  ective induction of chondrogenesis, the chondrogenic 
phenotype and molecular proﬁ  le achieved by AT and BM 
MSCs under appropriate conditions were found to be 
similar [65,89]. Th   e chondrogenic induction of MSCs in 
pellet culture with TGFβ3 is accompanied by an 
undesired up-regulation of hypertrophy-associated marker 
molecules, such as collagen type X and the matrix metallo-
proteinase MMP13, and by an activation of alkaline 
phosphatase (ALP) activity in vitro [65,96,100,106]. After 
ectopic transplantation into subcutaneous pouches of 
severe combined immuno  deﬁ   cient (SCID) mice, the 
hyper  trophic phenotype of diﬀ  erentiated pellets of both 
AT and BM MSCs leads to pronounced matrix 
calciﬁ  cation accompanied by vascular invasion and even 
micro-ossicle formation [89,106]. Common in vitro 
protocols of chondrogenesis thus produce MSC-derived 
chondrocytes that undergo premature hypertrophy and 
develop into transient endochondral cartilage, instead of 
stable articular cartilage-like tissue. As AT MSCs, in spite 
of their origin, mineralized their surrounding matrix in 
vivo to an extent similar to BM MSCs, the predisposition 
for osteogenesis and matrix calciﬁ  cation does not appear 
to be due to an origin of MSCs from bone.
In vitro, SM MSCs showed a tendency identical to 
those of MSCs from AT and BM to induce expression of 
osteogenic genes [105] and collagen type X after 
chondrogenic diﬀ   erentiation [52]. Under TGFβ3 and 
BMP6, the mean up-regulation of ALP activity was lower 
in SM MSCs than in AT and BM MSCs, but ALP activity 
in SM MSCs cell populations displayed extremely high 
donor variability compared with other MSCs, ranging 
from negative to very strong signals [52]. In vivo, cell 
populations that showed low ALP activity in vitro 
displayed low calciﬁ   cation, and this was surprisingly 
accompanied by a loss of already deposited collagen type 
II protein, possibly due to high MMP2, 3 and 13 activity. 
Th  e MSCs in these transplants thus lost their diﬀ  er-
entiated phenotype, while SM MSCs from other donors, 
which displayed high ALP activity in vitro, showed 
calciﬁ  cation in a similar way as AT and BM MSCs [52]. 
Th   e cause of this variability of phenotypes in SM MSCs 
after chondrogenic induction is unknown. Although SM 
MSCs show a diﬀ   erent phenotype than AT and BM 
MSCs after chondrogenesis in vitro, their origin from the 
joint environment appears not to be suﬃ   cient to program 
them towards a stable chondrogenic phenotype.
Undesired hypertrophic development of expanded 
MSCs seems no concern in vivo in a cartilage micro-
environment where expanded animal MSCs spontan-
eously mature into collagen type II-positive and collagen 
type X-negative chondrocytes [107]. In vitro co-culture 
experiments with articular chondrocytes demonstrate 
that the hypertrophic diﬀ   erentiation of MSCs can be 
inhibited by soluble factors secreted from chondrocytes, 
and parathyroid hormone-related protein (PTHrP) may 
be a candidate molecule for involvement in this inhibition 
[108]. PTHrP1-34 displays an inhibitory action on the 
TGFβ-induced hypertrophic diﬀ  erentiation of MSCs in 
vitro [90]. As a counteractor of Indian hedgehog, which is 
up-regulated during chondrogenesis of MSCs, it could 
represent an important factor for the stabilization of an 
articular phenotype in MSCs. Further in vivo and co-culture 
experiments may enable identiﬁ  cation of factors that are 
active in the microenvironment of cartilage and have the 
ability to lock cells in a hyaline chondrogenic stage.
Conclusion
Despite the growth of knowledge on the origin and 
composition of MSC populations from diﬀ  erent tissues, 
their heterogeneity is poorly understood. Transcriptional 
and epigenetic analyses of diﬀ   erent MSC populations 
reveal very similar proﬁ   les. However, diﬀ  erences  in 
expressed growth factors or active pathways between 
MSCs from diﬀ  erent sources could explain the diﬀ  erent 
requirements for the induction of chondrogenesis. 
Conditions allowing eﬃ   cient  chondrogenic  in vitro 
diﬀ  erentiation of MSCs from AT, BM and SM have been 
described. For long-lasting cell therapy in cartilage it is, 
however, essential to be able to achieve a stable 
chondrogenic phenotype. Th  e endochondral pathway 
triggered in MSCs during in vitro chondrogenesis and 
the ﬁ  brous dediﬀ  erentiation observed for some SM MSC 
populations therefore merit more thorough analysis. A 
better understanding of articular cartilage diﬀ  erentiation 
should permit determination of the conditions necessary 
for stable chondrogenic diﬀ  erentiation of MSCs.
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